We are live on ! Find out more
MPM BioImpact

MPM BioImpact Portfolio holdings

AUM $1.35B Turnover 42.55%
1-Year Est. Return 172.14%
 

MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.

This Fund
S&P 500
This Quarter Est. Return
+44.98%
1 Year Est. Return
+172.14%
3 Year Est. Return
+619.29%
5 Year Est. Return
+756.25%
10 Year Est. Return
–
AUM
$874M
AUM Growth
+$263M
Cap. Flow
+$99.1M
Cap. Flow %
11.34%
Top 10 Hldgs %
49.85%
Holding
55
New
15
Increased
6
Reduced
16
Closed
17
Avg Time Held
0.8 years
Top 10 Avg Time Held
0.9 years
Top 20 Avg Time Held
0.6 years

Top Buys

Rank Stock Value
1
QURE icon
uniQure
QURE
+$53.3M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$45.7M
3
LQDA icon
Liquidia
LQDA
+$34.2M
4
CRVS icon
Corvus Pharmaceuticals
CRVS
+$21.6M
5
URGN icon
UroGen Pharma
URGN
+$17.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
CGEM icon
1
Cullinan Therapeutics
CGEM
$576M
$79.2M 9.06%
7,648,268
– –
2021 Q1
19 quarters
MDGL icon
2
Madrigal Pharmaceuticals
MDGL
$8.81B
$56.4M 6.45%
96,780
-3,635
-4% -$1.86M
2025 Q1
3 quarters
LQDA icon
3
Liquidia
LQDA
$4.9B
$48.3M 5.53%
1,400,869
+1,200,869
+600% +$34.2M
2025 Q3
1 quarter
TRVI icon
4
Trevi Therapeutics
TRVI
$1.91B
$41.2M 4.71%
3,287,087
-119,868
-4% -$1.39M
2024 Q1
7 quarters
EWTX icon
5
Edgewise Therapeutics
EWTX
$4.38B
$41.1M 4.7%
1,655,256
-65,485
-4% -$1.31M
2024 Q1
7 quarters
RVMD icon
6
Revolution Medicines
RVMD
$35B
$40.3M 4.61%
505,672
+189,950
+60% +$12.5M
2021 Q3
17 quarters
AGIO icon
7
Agios Pharmaceuticals
AGIO
$1.66B
$35.5M 4.06%
+1,303,373
New +$45.7M
2025 Q4
0 quarters
QURE icon
8
uniQure
QURE
$1.36B
$33.1M 3.78%
+1,381,628
New +$53.3M
2025 Q4
0 quarters
PTCT icon
9
PTC Therapeutics
PTCT
$4.71B
$32.7M 3.74%
430,013
-8,464
-2% -$615K
2024 Q3
5 quarters
SNDX icon
10
Syndax Pharmaceuticals
SNDX
$790M
$28.1M 3.22%
1,337,702
-37,972
-3% -$662K
2025 Q3
1 quarter
DYN icon
11
Dyne Therapeutics
DYN
$2.92B
$27.5M 3.15%
1,405,388
-40,973
-3% -$776K
2025 Q2
2 quarters
TARS icon
12
Tarsus Pharmaceuticals
TARS
$3.6B
$26.9M 3.08%
328,869
-12,627
-4% -$943K
2025 Q2
2 quarters
STOK icon
13
Stoke Therapeutics
STOK
$1.76B
$24.4M 2.8%
770,289
-19,409
-2% -$583K
2024 Q3
5 quarters
ALMS icon
14
Alumis
ALMS
$517M
$23.4M 2.68%
+2,401,992
New +$16.8M
2025 Q4
0 quarters
URGN icon
15
UroGen Pharma
URGN
$1.37B
$22M 2.52%
941,378
+806,378
+597% +$17.5M
2025 Q3
1 quarter
XENE icon
16
Xenon Pharmaceuticals
XENE
$3.64B
$21.8M 2.49%
485,620
-17,778
-4% -$747K
2024 Q3
5 quarters
PVLA icon
17
Palvella Therapeutics
PVLA
$2.11B
$21.5M 2.46%
205,745
+138,322
+205% +$11.8M
2025 Q3
1 quarter
NTRA icon
18
Natera
NTRA
$39.6B
$21.4M 2.45%
93,551
-5,373
-5% -$1.12M
2024 Q1
7 quarters
CRVS icon
19
Corvus Pharmaceuticals
CRVS
$820M
$21.1M 2.42%
+2,743,671
New +$21.6M
2025 Q4
0 quarters
DBVT icon
20
DBV Technologies
DBVT
$567M
$19.1M 2.19%
996,825
-57,679
-5% -$901K
2025 Q2
2 quarters
RLAY icon
21
Relay Therapeutics
RLAY
$3.58B
$18.9M 2.16%
2,232,451
-50,229
-2% -$358K
2023 Q1
11 quarters
GLUE icon
22
Monte Rosa Therapeutics
GLUE
$739M
$18.4M 2.11%
+1,173,376
New +$15.8M
2025 Q4
0 quarters
DRUG icon
23
Bright Minds Biosciences
DRUG
$202M
$18M 2.06%
+230,147
New +$15.4M
2025 Q4
0 quarters
PTGX icon
24
Protagonist Therapeutics
PTGX
$7.95B
$17.4M 1.99%
+199,471
New +$16.3M
2025 Q4
0 quarters
ENGN icon
25
enGene Therapeutics
ENGN
$115M
$16.6M 1.9%
1,840,898
+1,310,599
+247% +$10.5M
2025 Q3
1 quarter

Similar funds

MPM BioImpact's Q4 2025 Portfolio in Review

As of Q4 2025, MPM BioImpact held 55 positions worth $874M, up 43% from $611M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

MPM BioImpact deployed $99.1M of net new capital in Q4 2025, opening 15 new positions and adding to 6 existing holdings. Its largest new stake was uniQure: 1,381,628 shares worth $33.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $13.3M trimmed.

  • MPM BioImpact's largest Q4 2025 buy was uniQure: 1,381,628 shares worth $33.1M.
  • MPM BioImpact added most to Liquidia in Q4 2025, an estimated $34.2M increase.
  • MPM BioImpact's biggest Q4 2025 reduction was Sarepta Therapeutics, cutting an estimated $13.3M.
  • MPM BioImpact fully exited Avidity Biosciences in Q4 2025, selling an estimated $33.1M.
  • MPM BioImpact's ten largest holdings make up 50% of its $874M portfolio in Q4 2025.
  • MPM BioImpact opened 15 new positions and closed 17 in Q4 2025.
  • MPM BioImpact's portfolio value rose 43% quarter-over-quarter to $874M.

Based on MPM BioImpact's 13F filing for Q4 2025, filed 17 Feb 2026.